ALEXANDRIA, Va., Aug. 26 -- United States Patent no. 12,396,944, issued on Aug. 26, was assigned to CAMURUS AB (Lund, Sweden).
"Injectable buprenorphine formulation" was invented by Fredrik Tiberg (Lund, Sweden), Markus Johnsson (Lund, Sweden) and Ian Harwigsson (Lund, Sweden).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides an injectable liquid formulation comprising: a) a lipid controlled-release matrix comprising at least 50% triacyl lipids; b) at least one oxygen containing organic solvent; c) at least 16% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. The invention further provides a controlled-rele...